These findings were in line with recent studies which have shown that immune abnormalities play an important role in tumor evasion, and provide rationale for the use of immune checkpoint inhibitors such as PD‐1 and CLTA‐4 inhibitors for the treatment of PTCL patients.22 This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.